Call Today for a FREE Consultation
Ball, Bonholtzer & Evans
Se Habla Español 626-817-6453

Pharmaceutical Litigation: Class Action Lawsuit Filed Against Impax Laboratories And Officers

Class action lawsuit claims Impax Laboratories and its' officers violated federal security laws under the Exchange Act. 

August 13, 2014 via Newswire A class action lawsuit has been filed against Impax Laboratories, Inc. ("Impax" or the "Company") (Nasdaq:IPXL) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-03673, is on behalf of a class consisting of all persons or entities who purchased Impax securities between May 20, 2013 and July 28, 2014, inclusive (the "Class Period"). This pharmaceutical litigation lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"). If you are a shareholder who purchased Impax securities during the Class Period, you have until October 13, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained here. Impax is a specialty pharmaceutical company engaged in the development, manufacture and marketing of bio-equivalent pharmaceutical products, referred to as generic products, in addition to the development of proprietary branded products. The Company operates in two segments, referred to as the "Global Pharmaceuticals Division" ("Global Division") and the "Impax Pharmaceuticals Division" ("Impax Division"). The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the quality control at the Company's Taiwan production facility. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: () the Company failed to maintain proper quality control and manufacturing practices at its Taiwan facility in violation of current Good Manufacturing Practices ("cGMP"); () the manufacturing deficiencies at the Taiwan facility could have a material adverse impact on the Company's ability to successfully launch its new drug, RYTARY; (3) the manufacturing deficiencies at the Taiwan facility jeopardized the Company's ability to manufacture, sell, and distribute generic pharmaceutical products; and (4) based upon the above, Defendants lacked a reasonable basis for their positive statements about the Company and its outlook, including statements about its ability to launch RYTARY. On July 29, 2014, Impax announced that the FDA completed an inspection of the Company's Taiwan facility. The FDA's inspection covered two areas. First, it covered a Pre-Approval Inspection for RYTARY, given the critical importance of the Taiwan facility to the manufacturing processes of the Company's drug candidate. Moreover, it included a general good manufacturing practices inspection. Based on its inspection, the FDA issued a Form 483 (a form used by the FDA to document and communicate deficiencies in a company's manufacturing quality-control system), stating that it had found "ten inspectional observations," or deficiencies, at the Taiwan facility. On this news, the Company's shares fell $4.27, or over 15.23%, to close at $23.76 on July 29, 2014. Originally posted on

  • America's Top 100 Attorneys
  • Rated By SuperLawyers Stephen C. Ball 11 Years In A Row 2005-2006
  • American Board Of Trial Advocates
  • The National Top 100 Trial Lawyers Trial Lawyers
Email Us For A Response

Contact Us For The Help You Need

Bold labels are required.

Contact Information

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.


Privacy Policy


Ball, Bonholtzer & Evans
300 North Lake Avenue Suite 1100
Pasadena, CA 91101

Phone: 626-817-6453
Fax: 626-793-3198
Pasadena Law Office Map